Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients

Adrian Rosenberg, Oluwarotimi S. Nettey, Pooja Gogana, Ujalla Sheikh, Virgilia Macias, Andre Kajdacsy-Balla, Roohollah Sharifi, Rick A Kittles, Adam B. Murphy

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the correlation between serum 25 hydroxyvitamin D, prostatic 25 hydroxyvitamin D, and serum 1,25 dihydroxyvitamin D, and their respective associations with prostatic tumor proliferation at the time of radical prostatectomy. Methods: In this cross-sectional analysis of 119 men undergoing radical prostatectomy, serum from whole blood and expressed prostatic fluid was collected on the day of surgery. Tumor proliferation was measured in the dominant tumor on formalin-fixed prostatectomy tissues by immunohistochemical staining for Ki67 and quantified by Aperio imaging analysis. Results: The sample included 88 African Americans (74%) and 31 (26%) European Americans. Serum and prostatic levels of 25 hydroxyvitamin D were correlated with each other (Spearman’s rho (ρ) = 0.27, p = 0.004), and there was also a correlation between serum 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D (ρ = 0.34, p < 0.001). Serum and prostatic 25 hydroxyvitamin D levels were not correlated with Ki67 staining in tumor cells. Serum 1,25 dihydroxyvitamin D was inversely correlated with Ki67 staining in tumor cells (ρ = − 0.30, p = 0.002). On linear regression, serum 1,25 dihydroxyvitamin D was negatively associated with Ki67 staining in tumor cells (β − 0.46, 95% CI − 0.75, − 0.04, p = 0.04). Conclusion: The correlation between physiologic serum levels of 25 hydroxyvitamin D with both prostatic 25 hydroxyvitamin D and serum 1,25 dihydroxyvitamin D suggests that serum levels are reasonable biomarkers of vitamin D status. Furthermore, serum 1,25 dihydroxyvitamin D has an inverse association with Ki67 staining in tumor cells at physiologic levels and may protect against tumor progression.

Original languageEnglish (US)
Pages (from-to)207-214
Number of pages8
JournalCancer Causes and Control
Volume30
Issue number2
DOIs
StatePublished - Feb 15 2019
Externally publishedYes

Fingerprint

Prostatectomy
Staining and Labeling
Serum
Neoplasms
1,25-dihydroxyvitamin D
25-hydroxyvitamin D
Ambulatory Surgical Procedures
Vitamin D
African Americans
Formaldehyde
Linear Models
Cross-Sectional Studies
Biomarkers

Keywords

  • African American
  • Proliferation
  • Prostate cancer
  • Vitamin D deficiency

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients. / Rosenberg, Adrian; Nettey, Oluwarotimi S.; Gogana, Pooja; Sheikh, Ujalla; Macias, Virgilia; Kajdacsy-Balla, Andre; Sharifi, Roohollah; Kittles, Rick A; Murphy, Adam B.

In: Cancer Causes and Control, Vol. 30, No. 2, 15.02.2019, p. 207-214.

Research output: Contribution to journalArticle

Rosenberg, Adrian ; Nettey, Oluwarotimi S. ; Gogana, Pooja ; Sheikh, Ujalla ; Macias, Virgilia ; Kajdacsy-Balla, Andre ; Sharifi, Roohollah ; Kittles, Rick A ; Murphy, Adam B. / Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients. In: Cancer Causes and Control. 2019 ; Vol. 30, No. 2. pp. 207-214.
@article{0592c58dcc364066b283826de5c92136,
title = "Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients",
abstract = "Purpose: To investigate the correlation between serum 25 hydroxyvitamin D, prostatic 25 hydroxyvitamin D, and serum 1,25 dihydroxyvitamin D, and their respective associations with prostatic tumor proliferation at the time of radical prostatectomy. Methods: In this cross-sectional analysis of 119 men undergoing radical prostatectomy, serum from whole blood and expressed prostatic fluid was collected on the day of surgery. Tumor proliferation was measured in the dominant tumor on formalin-fixed prostatectomy tissues by immunohistochemical staining for Ki67 and quantified by Aperio imaging analysis. Results: The sample included 88 African Americans (74{\%}) and 31 (26{\%}) European Americans. Serum and prostatic levels of 25 hydroxyvitamin D were correlated with each other (Spearman’s rho (ρ) = 0.27, p = 0.004), and there was also a correlation between serum 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D (ρ = 0.34, p < 0.001). Serum and prostatic 25 hydroxyvitamin D levels were not correlated with Ki67 staining in tumor cells. Serum 1,25 dihydroxyvitamin D was inversely correlated with Ki67 staining in tumor cells (ρ = − 0.30, p = 0.002). On linear regression, serum 1,25 dihydroxyvitamin D was negatively associated with Ki67 staining in tumor cells (β − 0.46, 95{\%} CI − 0.75, − 0.04, p = 0.04). Conclusion: The correlation between physiologic serum levels of 25 hydroxyvitamin D with both prostatic 25 hydroxyvitamin D and serum 1,25 dihydroxyvitamin D suggests that serum levels are reasonable biomarkers of vitamin D status. Furthermore, serum 1,25 dihydroxyvitamin D has an inverse association with Ki67 staining in tumor cells at physiologic levels and may protect against tumor progression.",
keywords = "African American, Proliferation, Prostate cancer, Vitamin D deficiency",
author = "Adrian Rosenberg and Nettey, {Oluwarotimi S.} and Pooja Gogana and Ujalla Sheikh and Virgilia Macias and Andre Kajdacsy-Balla and Roohollah Sharifi and Kittles, {Rick A} and Murphy, {Adam B.}",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s10552-019-1128-2",
language = "English (US)",
volume = "30",
pages = "207--214",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients

AU - Rosenberg, Adrian

AU - Nettey, Oluwarotimi S.

AU - Gogana, Pooja

AU - Sheikh, Ujalla

AU - Macias, Virgilia

AU - Kajdacsy-Balla, Andre

AU - Sharifi, Roohollah

AU - Kittles, Rick A

AU - Murphy, Adam B.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose: To investigate the correlation between serum 25 hydroxyvitamin D, prostatic 25 hydroxyvitamin D, and serum 1,25 dihydroxyvitamin D, and their respective associations with prostatic tumor proliferation at the time of radical prostatectomy. Methods: In this cross-sectional analysis of 119 men undergoing radical prostatectomy, serum from whole blood and expressed prostatic fluid was collected on the day of surgery. Tumor proliferation was measured in the dominant tumor on formalin-fixed prostatectomy tissues by immunohistochemical staining for Ki67 and quantified by Aperio imaging analysis. Results: The sample included 88 African Americans (74%) and 31 (26%) European Americans. Serum and prostatic levels of 25 hydroxyvitamin D were correlated with each other (Spearman’s rho (ρ) = 0.27, p = 0.004), and there was also a correlation between serum 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D (ρ = 0.34, p < 0.001). Serum and prostatic 25 hydroxyvitamin D levels were not correlated with Ki67 staining in tumor cells. Serum 1,25 dihydroxyvitamin D was inversely correlated with Ki67 staining in tumor cells (ρ = − 0.30, p = 0.002). On linear regression, serum 1,25 dihydroxyvitamin D was negatively associated with Ki67 staining in tumor cells (β − 0.46, 95% CI − 0.75, − 0.04, p = 0.04). Conclusion: The correlation between physiologic serum levels of 25 hydroxyvitamin D with both prostatic 25 hydroxyvitamin D and serum 1,25 dihydroxyvitamin D suggests that serum levels are reasonable biomarkers of vitamin D status. Furthermore, serum 1,25 dihydroxyvitamin D has an inverse association with Ki67 staining in tumor cells at physiologic levels and may protect against tumor progression.

AB - Purpose: To investigate the correlation between serum 25 hydroxyvitamin D, prostatic 25 hydroxyvitamin D, and serum 1,25 dihydroxyvitamin D, and their respective associations with prostatic tumor proliferation at the time of radical prostatectomy. Methods: In this cross-sectional analysis of 119 men undergoing radical prostatectomy, serum from whole blood and expressed prostatic fluid was collected on the day of surgery. Tumor proliferation was measured in the dominant tumor on formalin-fixed prostatectomy tissues by immunohistochemical staining for Ki67 and quantified by Aperio imaging analysis. Results: The sample included 88 African Americans (74%) and 31 (26%) European Americans. Serum and prostatic levels of 25 hydroxyvitamin D were correlated with each other (Spearman’s rho (ρ) = 0.27, p = 0.004), and there was also a correlation between serum 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D (ρ = 0.34, p < 0.001). Serum and prostatic 25 hydroxyvitamin D levels were not correlated with Ki67 staining in tumor cells. Serum 1,25 dihydroxyvitamin D was inversely correlated with Ki67 staining in tumor cells (ρ = − 0.30, p = 0.002). On linear regression, serum 1,25 dihydroxyvitamin D was negatively associated with Ki67 staining in tumor cells (β − 0.46, 95% CI − 0.75, − 0.04, p = 0.04). Conclusion: The correlation between physiologic serum levels of 25 hydroxyvitamin D with both prostatic 25 hydroxyvitamin D and serum 1,25 dihydroxyvitamin D suggests that serum levels are reasonable biomarkers of vitamin D status. Furthermore, serum 1,25 dihydroxyvitamin D has an inverse association with Ki67 staining in tumor cells at physiologic levels and may protect against tumor progression.

KW - African American

KW - Proliferation

KW - Prostate cancer

KW - Vitamin D deficiency

UR - http://www.scopus.com/inward/record.url?scp=85061189386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061189386&partnerID=8YFLogxK

U2 - 10.1007/s10552-019-1128-2

DO - 10.1007/s10552-019-1128-2

M3 - Article

C2 - 30730018

AN - SCOPUS:85061189386

VL - 30

SP - 207

EP - 214

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 2

ER -